Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.87 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | BMX | P51813 | 1/20 | 0.58 |
| ▸ | ITK | Q08881 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19573478 | 0.96 | BTK (0.85) | BTKEGFRBMXITK | |
| SCHEMBL15472580 | 0.93 | BTK (1.00) | BTKEGFRBMXITK | |
| SCHEMBL15472615 | 0.85 | BTK (1.00) | BTKEGFRBMXITK | |
| SCHEMBL20007850 | 0.85 | BTK (0.84) | BTKEGFRBMXITK | |
| SCHEMBL4767842 | 0.85 | BTK (1.00) | BTKEGFR | |
| SCHEMBL11957358 | 0.84 | BTK (0.98) | BTK | |
| SCHEMBL15472587 | 0.83 | BTK (1.00) | BTK | |
| SCHEMBL15472609 | 0.82 | BTK (1.00) | BTK | |
| SCHEMBL28132482 | 0.81 | BTK (0.81) | BTKEGFR | |
| SCHEMBL16597655 | 0.80 | BTK (0.69) | BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875852-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-29 | — | — | US | disclosed |
| US-20190112302-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-04-18 | — | — | US | disclosed |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | BTK 1/4885EGFR 357/4885BMX 4/4885 |
| US-10875852-B2 | Heteroaromatic compounds as BTK inhibitors | BTK, SYK, LCK | BTK 1/4885EGFR 357/4885BMX 4/4885 |
| US-20190112302-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | BTK 1/4885EGFR 357/4885BMX 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.